secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2024-01-25T23:59:59+00:00
Accession:  0001070081-24-000006
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics' Translarna faces withdrawal in Europe after CHMP negative opinion on renewal
--------------------------------------------------------------------------------

- CHMP issued negative opinion on renewal of conditional marketing authorization for Translarna (ataluren) after re-examination procedure.
- Negative opinion applies to Translarna for nonsense mutation Duchenne Muscular Dystrophy (nmDMD).
- European Commission to adopt the opinion within 67 days, resulting in withdrawal of Translarna in Europe.
- CEO Matthew B. Klein expressed disappointment, stating decision is against patient community and expert physicians.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008124000006/0001070081-24-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008124000006/tmb-20240125x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-24-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer